Total Payments
$12,534
2024 Payments
$1,478
Companies
32
Transactions
650
Medicare Patients
2,324
Medicare Billing
$332,389
Payment Breakdown by Category
Food & Beverage$11,684 (93.2%)
Education$506.47 (4.0%)
Other$343.88 (2.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $11,684 | 618 | 93.2% |
| Education | $506.47 | 15 | 4.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $343.88 | 17 | 2.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ViiV Healthcare Company | $2,813 | 147 | $0 (2024) |
| Gilead Sciences, Inc. | $1,599 | 74 | $0 (2024) |
| Melinta Therapeutics, LLC | $1,416 | 84 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,134 | 70 | $0 (2024) |
| Theratechnologies Inc. | $947.92 | 47 | $0 (2024) |
| Janssen Biotech, Inc. | $727.73 | 37 | $0 (2023) |
| ABBVIE INC. | $616.48 | 32 | $0 (2024) |
| Napo Pharmaceuticals Inc | $528.60 | 26 | $0 (2023) |
| Janssen Products, LP | $433.96 | 6 | $0 (2022) |
| Theravance Biopharma, Inc. | $397.96 | 30 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,478 | 72 | ViiV Healthcare Company ($413.73) |
| 2023 | $1,555 | 75 | ViiV Healthcare Company ($350.16) |
| 2022 | $1,841 | 85 | ViiV Healthcare Company ($247.09) |
| 2021 | $1,558 | 74 | ViiV Healthcare Company ($389.05) |
| 2020 | $1,691 | 91 | ViiV Healthcare Company ($517.99) |
| 2019 | $1,453 | 80 | ViiV Healthcare Company ($252.96) |
| 2018 | $1,499 | 96 | ViiV Healthcare Company ($335.13) |
| 2017 | $1,460 | 77 | ViiV Healthcare Company ($306.78) |
All Payment Transactions
650 individual payment records from CMS Open Payments — Page 1 of 26
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | ABBVIE INC. | DALVANCE (Drug), TEFLARO, AVYCAZ | Food and Beverage | In-kind items and services | $8.40 | General |
| Category: ANTI-INFECTIVE | ||||||
| 12/12/2024 | ABBVIE INC. | DALVANCE (Drug), TEFLARO, AVYCAZ | Food and Beverage | In-kind items and services | $5.49 | General |
| Category: ANTI-INFECTIVE | ||||||
| 12/10/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $19.11 | General |
| 12/06/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $11.48 | General |
| Category: HIV | ||||||
| 12/05/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $16.45 | General |
| 11/19/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Orbactiv | Food and Beverage | In-kind items and services | $17.51 | General |
| Category: ANTIFUNGALS | ||||||
| 11/18/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $7.69 | General |
| Category: HIV | ||||||
| 11/14/2024 | ABBVIE INC. | DALVANCE (Drug), TEFLARO, AVYCAZ | Food and Beverage | In-kind items and services | $33.80 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/05/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $26.51 | General |
| Category: HIV | ||||||
| 10/29/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $29.79 | General |
| 10/25/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug), ZERBAXA | Food and Beverage | In-kind items and services | $20.48 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/17/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $28.27 | General |
| 10/15/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $27.37 | General |
| Category: HIV | ||||||
| 10/08/2024 | Merck Sharp & Dohme LLC | DELSTRIGO (Drug) | Food and Beverage | In-kind items and services | $16.46 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/03/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Orbactiv, Vabomere | Food and Beverage | In-kind items and services | $14.02 | General |
| Category: ANTIFUNGALS | ||||||
| 10/03/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $4.63 | General |
| Category: HIV | ||||||
| 09/17/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $23.10 | General |
| Category: HIV | ||||||
| 09/10/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $26.24 | General |
| Category: Infectious Diseases | ||||||
| 09/09/2024 | ABBVIE INC. | AVYCAZ (Drug), TEFLARO, DALVANCE | Food and Beverage | In-kind items and services | $29.18 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/06/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $29.48 | General |
| 09/05/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $25.77 | General |
| Category: HIV | ||||||
| 09/03/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Kimyrsa, Orbactiv | Food and Beverage | In-kind items and services | $19.90 | General |
| Category: ANTIFUNGALS | ||||||
| 08/26/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $27.64 | General |
| Category: Infections and Infectious Diseases | ||||||
| 08/06/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $28.83 | General |
| 08/01/2024 | La Jolla Pharmaceutical Company | XERAVA (Drug) | Food and Beverage | In-kind items and services | $29.92 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 469 | 869 | $177,065 | $73,861 |
| 2022 | 8 | 532 | 987 | $198,897 | $77,991 |
| 2021 | 9 | 625 | 1,164 | $232,149 | $94,201 |
| 2020 | 9 | 698 | 1,147 | $227,184 | $86,336 |
Total Patients
2,324
Total Services
4,167
Medicare Billing
$332,389
Procedure Codes
32
All Medicare Procedures & Services
32 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 167 | 431 | $70,950 | $28,122 | 39.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 100 | 203 | $47,705 | $22,068 | 46.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 87 | 87 | $25,230 | $9,233 | 36.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 53 | 79 | $18,565 | $7,400 | 39.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 49 | 49 | $11,515 | $4,829 | 41.9% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 13 | 20 | $3,100 | $2,209 | 71.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 186 | 451 | $74,415 | $26,352 | 35.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 100 | 222 | $52,530 | $23,214 | 44.2% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 95 | 95 | $27,550 | $10,299 | 37.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 66 | 125 | $29,375 | $10,189 | 34.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 38 | 38 | $8,930 | $3,775 | 42.3% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 22 | 31 | $4,805 | $3,465 | 72.1% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 14 | 14 | $807.94 | $466.70 | 57.8% |
| 90686 | Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage | Office | 2022 | 11 | 11 | $484.00 | $230.87 | 47.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 196 | 536 | $88,440 | $32,230 | 36.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 126 | 232 | $55,969 | $24,977 | 44.6% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 138 | 138 | $40,020 | $15,449 | 38.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 55 | 124 | $29,140 | $10,451 | 35.9% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 38 | 62 | $9,505 | $7,230 | 76.1% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 26 | 26 | $6,110 | $2,632 | 43.1% |
| 0003A | Fee covid-19 vac 1 booster | Office | 2021 | 14 | 14 | $1,269 | $609.21 | 48.0% |
| G0008 | Administration of influenza virus vaccine | Office | 2021 | 21 | 21 | $1,211 | $396.37 | 32.7% |
| 90686 | Vaccine for influenza for administration into muscle, 0.5 ml dosage, quadrivalent, preservation free | Office | 2021 | 11 | 11 | $484.00 | $225.83 | 46.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 227 | 478 | $78,870 | $28,701 | 36.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 120 | 201 | $47,627 | $18,100 | 38.0% |
About Dr. Paul Ramilo, MD
Dr. Paul Ramilo, MD is a Infectious Disease healthcare provider based in Centreville, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1821045501.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Paul Ramilo, MD has received a total of $12,534 in payments from pharmaceutical and medical device companies, with $1,478 received in 2024. These payments were reported across 650 transactions from 32 companies. The most common payment nature is "Food and Beverage" ($11,684).
As a Medicare-enrolled provider, Ramilo has provided services to 2,324 Medicare beneficiaries, totaling 4,167 services with total Medicare billing of $332,389. Data is available for 4 years (2020–2023), covering 32 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Centreville, VA
- Active Since 05/28/2006
- Last Updated 04/12/2024
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1821045501
Products in Payments
- DOVATO (Drug) $1,317
- SYMTUZA (Drug) $691.98
- EGRIFTA (Drug) $682.85
- DALVANCE (Drug) $678.82
- Mytesi (Drug) $528.60
- CABENUVA (Biological) $479.89
- TRIUMEQ (Drug) $411.45
- VIBATIV (Drug) $397.96
- Baxdela (Drug) $360.42
- JULUCA (Drug) $336.40
- Kimyrsa (Drug) $335.35
- Orbactiv (Drug) $289.42
- Arikayce (Drug) $277.61
- TROGARZO (Drug) $265.07
- DIFICID (Drug) $255.15
- ISENTRESS (Drug) $236.75
- AVYCAZ (Drug) $230.97
- ZERBAXA (Drug) $225.74
- Vabomere (Drug) $218.02
- Rezzayo (Drug) $213.08
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.